Replies to post #4769 on Revance Therapeutics Inc (RVNC)

[mouton29]

However, prior to FDA approval this analyst had modeled the probably of success in CD at 70% (not 80%), a figure that I ridiculed in #msg-170173399.

The 70% was in a report in 2022. In March, 2023, the analyst bumped it to 80%:

Pipeline: On January 6th, 2022 the company announced the acceptance of the Daxxify sBLA to treat Cervical Dystonia (LINK), with a PDUFA date of 8/19/23. CD would represent the first therapeutic indication for Daxxify. We increase our POS to 80% from 70% and we model 2023 therapeutic revenue of $2.9mn vs. cons. $3.0mn.

Pipeline: On January 6th, 2022 the company announced the acceptance of the Daxxify sBLA to treat Cervical Dystonia (LINK), with a PDUFA date of 8/19/23. CD would represent the first therapeutic indication for Daxxify. We increase our POS to 80% from 70% and we model 2023 therapeutic revenue of $2.9mn vs. cons. $3.0mn.